Lymphact is a biopharmaceutical start-up focused on developing innovative personalized medical treatments.
We created a new technology platform which can generate autologous and heterologous cellular immune therapies for clinical applications – the DOT-Cells®.
|
|
|
PRODUCTS & SERVICES
After 5 years of pioneering research and development, we created a new technology platform which can generate autologous and heterologous cellular immune therapies for clinical applications – the DOT-Cells®.
DOT-Cells® can target not only cancer and virusinfected cells, but also chemotherapy-resistant cancer stem cells and viral reservoirs, believed to cause disease recurrence. An improved anti-tumour function and the absence of severe associated side effects are distinctive and unique features of our therapeutic approach. Our patents are deployed in the US, EU, Japan and China and our first product will target Leukaemia.
We successfully completed the pre-clinical trials and will enter the clinical stage of the project in the last quarter of 2015.
Of note, ouDOT-Cells®:
/ can be produced for a much lower cost than our main cell therapy competitors;
/ is simple and optimized for clinical large-scale production;
/ has broad application to several types of cancer diseases.
|
|
TARGET MARKETS / CLIENTS
Our first product is an autologous cell therapy, designed to treat patients with chronic lymphocytic leukemia (CLL). CLL is a disease that affects a specific type of white blood cells, called B lymphocytes. It is the most common leukemia in adults, representing around 35% of all leukemias.
The ultimate goal for Lymphact is launching the DOT-Cells® in the market. In order to do so, however, several steps have to be taken. We have already finalised all pre-clinical research for the CLL product, and we are currently composing the regulatory documents necessary for initiating the phase I/IIa Clinical Trial in Europe. Following this major milestone, Lymphact will continue the clinical development of the product, until, finally, submitting a market authorization application.
Concurrently, we shall develop other products, which must follow the same path. Ultimately, we expect to have a wide range of cellular products available for cancer sites with unmet medical needs, including allogeneic cell therapies.
|
